Business

Holding(s) in Company - Replacement

Holding(s) in Company - Replacement.

articleFaron Pharmaceuticals OyJune 25, 20243/company/faron-pharmaceuticals-oy/news/holdings-in-company-replacement-25
Holding(s) in Company - Replacement

About this update from Faron Pharmaceuticals Oy

[{"type":"text","content":"\n\n \n \n \n \nThe following amendment has been made to the 'Holding(s) in Company' announcement released on 24 June 2024 at 12:45 p.m. BST under RNS No 6230T.\n \nIn Section 7 of the TR-1: Standard form for notification of major holdings, the data in the rows  'Resulting situation on the date on which threshold was crossed or reached' and 'Position of previous notification (if applicable)' have been swapped to accurately reflect the reduction in holdings and the crossing of the percentage threshold.\n \nAll other details remain unchanged.\n \nThe full amended text is shown below.\n \n \nTR-1: Standard form for notification of major holdings\n \n\n\n\n\nNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i\n\n\n\n\n\n\n\n\n\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:\n\n\nFaron Pharmaceuticals Ltd\n \n\n\n\n\n1b. Please indicate if the issuer is a non-UK issuer  (please mark with an \"X\" if appropriate)\n\n\n\n\nNon-UK issuer\n\n\nx\n\n\n\n\n2. Reason for the notification (please mark the appropriate box or boxes with an \"X\")\n\n\n\n\nAn acquisition or disposal of voting rights\n\n\n\n\n\n\n\nAn acquisition or disposal of financial instruments\n\n\n\n\n\n\n\nAn event changing the breakdown of voting rights\n\n\n\n\n\n\n\nOther (please specify) iii: Change due the Share Offering\n\n\nx\n\n\n\n\n3. Details of person subject to the notification obligation iv\n\n\n\n\nName\n\n\nMarko Salmi\n\n\n\n\nCity and country of registered office (if applicable)\n\n\nTurku, Finland\n\n\n\n\n4. Full name of shareholder(s) (if different from 3.) v\n\n\n\n\nName\n\n\n\n\n\n\n\nCity and country of registered office (if applicable)\n\n\n\n\n\n\n\n5. Date on which the threshold was crossed or reached vi:\n\n\n20.6.2024\n\n\n\n\n6. Date on which issuer notified (DD/MM/YYYY):\n\n\n20.6.2024\n\n\n\n\n7. Total positions of person(s) subject to the notification obligation\n\n\n\n\n\n\n\n% of voting rights attached to shares (total of 8. A)\n\n\n% of voting rights through financial instruments\n(total of 8.B 1 + 8.B 2)\n\n\nTotal of both in % (8.A + 8.B)\n\n\nTotal number of voting rights held in issuer (8.A + 8.B) vii\n\n\n\n\nResulting situation on the ...

More updates from Faron Pharmaceuticals Oy